

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



**(43) International Publication Date
6 June 2002 (06.06.2002)**

PCT

(10) International Publication Number
WO 02/43662 A2

(51) International Patent Classification⁷:

A61K

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/44872

(22) International Filing Date: 29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

(71) **Applicant (for all designated States except US):**
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US)

(72) Inventor; and
(75) Inventor/Applicant (for US only): BENDICH, Adrienne
[US/US]; 1500 Littleton Road, Parsippany, NJ 07054 (US).

(74) **Agents:** DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/43662 A2

(54) Title: DIETARY COMPOSITION CONTAINING CONJUGATED LINOLEIC ACID AND CALCIUM FOR IMPROVED HEALTH

(57) Abstract: The invention provides a composition for oral administration comprising a mixture of conjugated linoleic acid (CLA), docosahexaenoic acid "DHA", vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors of cardiovascular disease, such as elevated serum cholesterol levels and high blood pressure.

5 **DIETARY COMPOSITION CONTAINING CONJUGATED LINOLEIC
ACID AND CALCIUM FOR IMPROVED HEALTH**

Field of the Invention

10 The present invention relates generally to a dietary supplement, and more particularly, to an oral supplement.

Background of the Invention

15 Cardiovascular disease (CVD) is generally recognized to be the primary killer of men and women in developed countries globally. The cost of these premature deaths is great both to the individuals and their families and to the health care system of the country as a whole. The risk factors for cardiovascular disease are well-recognized and include: higher than average serum cholesterol, elevated levels of LDL; a low level of HDL in proportion to the LDL level; higher than average 20 serum triglycerides; higher levels of lipid oxidation products creating plaques and streaks which cause blockages of coronary arteries. Another CVD risk factor, high blood pressure is also a risk factor for strokes.

25 Research has shown that reduction in these risk factors also reduces the risk of cardiovascular disease and its many costs. [See A. Bendich, R.J. Deckelbaum, eds. Preventive Nutrition: The Comprehensive Guide for Health Professionals. Totowa, NJ: Humana Press (2000); for example, K.C. Hayes. "Dietary Fat and Coronary Heart Disease."]

30 Dietary supplements are well known and recent research has uncovered a number of therapeutic uses therefor. For example, conjugated linoleic acid (CLA), a fatty acid found primarily in milk fat, has been found to be a naturally occurring anticarcinogen. [See, S. Reiner, "CLA: Does Fat Have a Silver Lining?", *Health Priorities*, 8(4): (1996), American Council on Science and Health]. Vitamin E is the major lipid-soluble antioxidant in the human body [L. Mosca, *et al.*, "Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to

oxidation in patients with coronary artery disease," J Am Coll Cardiol, 30:392-9 (1997)]. Vitamin C is another well-known anti-oxidant. See A. Bendich, L. Langseth, "The health effects of vitamin C supplementation: A Review" J. Am. Coll. Nutr. 14:124-36 (1995), [published errata appear in J Am Coll Nutr

- 5 Jun:14(3):218 (1995) and Aug:14(4):398 (1995)]. A variety of benefits have been described in connection with omega-3 fatty acids [W.E. Connor and S.L. Conner, "N-3 Fatty Acids from Fish and Plants: Primary and Secondary Prevention of Cardiovascular Disease", in: A. Bendich and R.J. Deckelbaum, eds. Preventive Nutrition]. Similarly, benefits of dietary supplementation with folic acid, vitamin 10 B6 and vitamin B12 have been described [S.A. Beresford and C.J. Boushey, "Homocyst(e)ine, Folic Acid and Cardiovascular Disease Risk", In: in: A. Bendich and R.J. Deckelbaum, eds. Preventive Nutrition]. Calcium status has also been found to be inversely associated with blood pressure. High blood pressure is another important risk factor for cardiovascular disease [D. A. McCarron and M.E. Reusser, 15 "Finding consensus in the dietary calcium-blood pressure debate," J. Am. Coll Nutr., 18:398S-405S (1999)].

There have been dietary compositions described in the past which contain specific vitamins or other supplements, either alone or in a variety of combinations. Many dietary supplements have been described in the art, but their efficacy in 20 preventing cardiovascular disease remains inadequate. As a result, in the field of CVD prevention, there is no single prior art composition which reduces the variety of risk factors associated with this pervasive disease and which has wide spread applicability to the population in developed countries.

25 Summary of the Invention

In one aspect, the present invention provides a novel composition which may be incorporated into an orally administered dietary supplement for the reduction of risk factors associated with CVD. The dietary composition of the invention represents a unique combination of active dietary factors (essential nutrients and 30 non-essential food components) that have never before been developed into a single supplement. This combination is surprisingly effective in the treatment of a variety

of risk factors which have been linked to heart attacks, particularly reduction of overall serum cholesterol levels, reductions in high blood pressure, increase in the HDL:LDL ratio, reduction of triglycerides and homocysteine levels, and prevention of lipid oxidation and the formation of plaques and streaks.

5 In one particular embodiment, the composition of this invention comprises the following dietary components: conjugated linoleic acid (CLA); vitamin E; vitamin C; docosahexanoic acid "DHA"; folic acid; vitamin B6 and vitamin B12, and calcium. In combination, each of these components, which independently reduce one or more of the risk factors for CVD, work synergistically to reduce the
10 risk of CVD more effectively than any of these components taken alone. Additionally, all of the components have wide safety margins, therefore it is expected that the combination of all of these active components will require a lower concentration of each component alone, and therefore, enhance the safety of the combination of these dietary factors.

15 In another aspect, the invention provides a pharmaceutical and/ or dietary composition containing the formulation described above in admixture with pharmaceutically acceptable base, and optionally containing other known agents including, but not limited to stabilizer agents, preservatives and emulsifiers. The compositions, according to this invention may be presented in different
20 embodiments, including but not limited to tablets, powders, chews, bars, and shakes or similar formulations.

In a further aspect of this invention, a method is provided for preparing the novel dietary compositions described herein and incorporating the same into orally administrated pharmaceutical compositions.

25 In yet a further aspect, this invention provides a process for treating individuals to reduce the risk factors for CVD comprising orally administering a pharmaceutical composition as described above.

Other aspects and advantages of the present invention will become apparent from the following detailed description thereof.

30

Detailed Description of the Invention

The present invention provides novel compositions comprised of combinations of selected mixtures of active dietary factors, including certain vitamins and other components, which are surprisingly effective in their ability to 5 reduce the risk factors of CVD and promote improved cardiovascular health. The oral administration of these compositions acts to reduce serum cholesterol levels and blood pressure, increase HDL levels in proportion to LDL levels, to protect lipids from oxidation thereby preventing the formation of plaques and streaks which block coronary arteries, and to lower both triglyceride levels and homocysteine levels. In 10 addition, it is believed that oral administration of the compositions of this invention acts to reduce the risk of stroke, as well as heart attack, in human adults.

The orally-administered compositions of this invention include those dietary admixtures in which the formulations is swallowed in any acceptable form. Conventional forms for this purpose include but are not limited to liquids, tablets, 15 effervescent tablets, pills, powders, wafers or premixed shakes. See Remington's Practice of Pharmacy, 11th Edition, (1956).

The novel compositions of the present invention are comprised of the following vitamins and dietary factors which in combination provide a surprising result in reducing the risk factors of CVD. The combination of dietary factors and 20 vitamins work synergistically to improve cardiovascular health to a great degree than expected. The essential components of the compositions are CLA, docosahexaenoic acid "DHA", vitamin E, vitamin C, folic acid, vitamin B6, vitamin B12, and calcium.

Suitably, the conjugated linoleic acid useful in the present invention refers to 25 any member of a group of several variants of linoleic acid (also termed octadecadienoic acid). CLA may be isolated from foods such as cheese and milk using methods known to those of skill in the art. Alternatively, CLA may be synthesized using known techniques. For example, CLA may be synthesized from 95% pure linoleic acid [D. DeVoney et al., "Trans-10,Cis-12 Octadecadienoic acid 30 increases lymphocyte proliferation", p. 56, 1998 Annual Report of the Food Research Institute]. Such synthesized CLA typically contains 43% c9, t11/t9,c11

and 44% t10,c12 octadecadienoate. CLA may also be purchased from a variety of commercial sources, e.g., CLA enriched for c9,t11/t9,,c11 (70.5% with no t10,c12 is available form Matreya, Inc); CLA may also be purchased from Peak Nutrition, Syracuse, NE. Typically, CLA is present in the composition of the invention in an 5 amount of about 250 mg to about 3000 mg; more desirably, about 300 mg to about 2000 mg, and most preferably, about 500 mg to about 1000 mg per dose. Advantageously, CLA is contributes to the ability of the composition of the invention to protect against cancer, and to modulate the immune system.

The composition of the invention further includes vitamin E, which may be 10 in any suitable form. Natural vitamin E can be isolated from vegetable oils, including corn, cottonseed, rapeseed, peanut, sunflower and soybean oil, or obtained from a variety of commercial sources. Natural vitamin E may be in the form d-alpha-tocopherol (RRR-alpha-tocopherol), or the acetate [d-alpha-tocopheryl acetate (RRR-alpha-tocopheryl acetate)] or succinate salt thereof [d-alpha-tocopheryl acid 15 succinate (RRR-alpha-tocopheryl acid succinate)], or may be in the form of natural mixed tocopherols [d-alpha-, d-beta-, d-gamma and d-delta-tocopherol]. Alternatively, synthetic vitamin E may be produced from petrochemicals in the form of dl-alpha-tocopherol (all-rac-alpha-tocopherol), or the acetate [dl-alpha-tocopheryl acetate, (all-rac-alpha-tocopheryl acetate)] or succinate salt thereof [dl-alpha-tocopheryl acid succinate (all-rac-alpha-tocopheryl acid succinate), or 20 mixtures thereof. Where reference is made herein to vitamin E, any of the natural or synthetic forms of the vitamin may be used, or combinations thereof. In the formulation of the invention, Vitamin E prevents the blockage of coronary arteries and other vessels within the body that result when oxidized lipids are permitted to 25 form [S.B. Kritchevsky et al, "Dietary antioxidants and carotid artery wall thickness", The ARIC Study. Atherosclerosis Risk in Communities Study, Circulation, 92:2142-50 (1995)]. Thus, vitamin E is a useful as an antioxidant [Jeng et al, Am. J. Clin. Nutr., 64:960-5 (1996); F.M. Steinberg and A. Chait, Am. J. Clin. Nutr., 68:319-27 (1998), [publ. erratum appears in Am J Clin Nutr., 30 Jun:69(6):1293 (1999)] Thus, vitamin E clearly is an important component in the formulation of the composition designed for the prevention of CVD. In one

embodiment, the composition of the invention contains about 50 IU to about 800 IU of vitamin E, and most preferably, about 100 IU.

Vitamin C is another component of the composition of the invention.

Vitamin C is an anti-oxidant which works synergistically with Vitamin E to protect 5 cellular components from oxidative damage leading to cardiovascular disease. Vitamin C optimizes the effects of Vitamin E to reduce the oxidation of lipids. Further, Vitamin C taken alone has been linked with a decreased risk of CVD as well as CVD mortality, possibly because of the reduction in systolic and diastolic blood pressure seen in those individuals taking large doses of the vitamin [S.J. Duffy 10 et al, "Treatment of hypertension with ascorbic acid", Lancet, 354:2048-9 (1999); P. Weber et al, "Vitamin C and human health - a review of recent data relevant to human requirements", Int. J. Vitam. Nutr. Res., 66:19-30 (1996)]. In one suitable embodiment, vitamin C is in the form of ascorbate or ascorbic acid, and is present in an amount of about 60 mg to about 1000 mg, or about 100 to about 500 mg.

15 The present invention further includes an omega-3 fatty acid which is known to cause reduction in triglycerides and increase in HDL levels. Most preferably, this omega-3 fatty acid is in the form of docosahexaenoic acid "DHA", which may be extracted from algae using known methods or purchased commercially. DHA is the longest omega-3 fatty acid and is known to be important in the functioning of every 20 cell membrane in the body. It is found in especially high concentration in the human brain and retina. DHA has also been seen to reduce the risk of ventricular arrhythmia that can result in sudden death. In one desirable embodiment, the composition of the invention contains about 125 mg to about 500 mg, and preferably about 230 to about 250 mg DHA. Alternatively, another omega-3 oil may be included in the 25 composition of the invention.

Folic acid (or a pharmaceutically acceptable salt thereof), vitamin B6 and 30 vitamin B12 are all involved in normal amino acid metabolism. Specifically, these vitamins have been known to significantly reduce elevated homocysteine levels that have been linked to an increased risk of CVD, as well as stroke, peripheral vascular disease and dementia. Most suitably, the composition of the invention contains

about 400 µg to about 1000 µg folic acid (or folate); about 2 mg to about 50 mg vitamin B6, preferably about 10 to 25 mg vitamin B6; and about 6 µg to about 1 mg vitamin B12.

Calcium has been associated with reducing systolic and diastolic blood pressure. The composition of this invention contains about 200 to about 100 mg of elemental calcium, which may be in the form of pharmaceutically acceptable salt thereof. In one desirable embodiment, calcium is present in the composition of the form of calcium carbonate.

Optionally, the eight active components discussed above may be admixed with other active ingredients. Preferably, however, these components are the only active ingredients in the composition of the invention.

One particularly desirable embodiment of the composition of the invention is provided in Example 1 below. However, the invention is not limited by this formulation, or by the ranges provided herein, which are intended for guidance only.

One of skill in the art can readily select other ranges, depending upon the delivery form (e.g., effervescent tablet vs. tablet), the age, and condition of the patient, among other factors.

A composition of the formulation of the invention may be used orally to treat and/or prevent risk factors of CVD and stroke, including reduction of high blood pressure and overall serum cholesterol.

While not wishing to be bound by theory, the inventors believe that the compositions work by acting at different sites and aspects of cardiovascular disease. High cholesterol, high LDL, elevated triglycerides, high blood pressure, low HDL, high homocysteine levels and oxidized lipids are all attacked by one or more of the dietary factors present in the oral formulation and act synergistically to reduce the risk factors of CVD. By affecting CVD risk factors at several sites and by different mechanisms of action, there is an enhancement of the effects of the supplement that is greater than the additive effect of the dietary factors. The dietary supplement

contains active ingredients that are safe, efficacious and cost-effective in lowering CVD risk factors.

The compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, 5 capsules, pills, powders, granules, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient. For oral administration either solid or fluid unit dosage forms can be prepared.

Powders are prepared quite simply by comminuting the active ingredient(s) to a suitably fine size and mixing with a similarly comminuted diluent. The diluent 10 can be an edible carbohydrate material such as lactose or starch. Advantageously, a sweetening agent or sugar is present as well as a flavoring oil.

Capsules are produced by preparing a powder mixture as hereinbefore described and filling into formed gelatin sheaths. Advantageously, as an adjuvant to the filling operation, a lubricant such as a talc, magnesium stearate, and the like is 15 added to the powder mixture before the filling operation.

Soft gelatin capsules are prepared by machine encapsulation of a slurry of active ingredients with an acceptable vegetable oil, light liquid petrolatum or other inert oil or triglyceride.

Tablets, chews and bars are made by preparing a powder mixture, granulating 20 or slugging, adding a lubricant and pressing into tablets, chews, or bars. The powder mixture is prepared by mixing an active ingredient, suitably comminuted, with a diluent or base such as starch, lactose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as corn syrup, gelatin solution, methylcellulose solution or acacia mucilage and forcing through a 25 screen. As an alternative to granulating, the powder mixture can be slugged, e.g., run through the tablet, bar or chew, machine and the resulting imperfectly formed tablets broken into pieces (slugs). The slugs can be lubricated to prevent sticking to the shape-forming dies by means of the addition of stearic acid, a stearic salt, talc or mineral oil. The lubricated mixture is then compressed into tablets, chews or bars,

as desired. Optionally, a tablet can be provided with a protective coating consisting of a sealing coat or enteric coat of shellac, a coating of sugar and methylcellulose and polish coating of carnauba wax. Advantageously, chews and bars may be mixing with a variety of flavorings, sweetening agents, or the like.

5 Fluid unit dosage forms for oral administration such as syrups, elixirs and suspensions can be prepared wherein each teaspoonful of composition contains a predetermined amount of active ingredient for administration. The water-soluble forms can be dissolved in an aqueous vehicle together with sugar, flavoring agents and preservatives to form a syrup. An elixir is prepared by using a hydroalcoholic vehicle with suitable sweeteners together with a flavoring agent. Suspensions can be prepared on the insoluble forms with a suitable vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.

10 In another embodiment, the invention provides a method of using the composition to improve the health of the heart and to reduce risk factors associated with cardiovascular disease by delivering to an individual the composition of the invention. Thus, delivery of the composition of the invention, e.g., by oral administration, is useful for preventing oxidation of low density lipoprotein (LDL), increasing high density lipoprotein (HDL), and for reducing total cholesterol. Delivery of the composition of the invention is also useful for reducing triglycerides and reducing homocysteine.

15 Desirably, the compositions of the invention are formulated such that an effective amount is delivered by two tablets (or other suitable formulation) a day. Suitably, these doses may be taken with meals, mixed into feed, or taken on an empty stomach. Generally improvement is observed after two weeks of daily use.

20 Several factors have been observed to interfere with the positive effects of dietary supplementation with the compositions of the invention, including smoking, eating a high fat diet, omitting dietary fibers or roughage from a daily diet and maintaining an essentially sedentary lifestyle.

The compositions of the present invention, in addition to their use in treating CVD in humans, may also be useful in treating non-human animals, particularly mammals. For example, these dietary supplements may be useful for companion animals such as dogs and cats, for cattle, horses, and pigs, among other animals.

5 The following example which demonstrates the compositions of the invention for illustrative purposes only and does not limit the scope of the invention. The compositions of this invention are anticipated to produce surprisingly good results in reducing a variety of risk factors associated with impaired cardiovascular conditions. As demonstrated in the following example, the compositions of the
10 invention have advantages over the prior art in safely lowering CVD risk factors in a cost effective manner.

Example

15 In one exemplary embodiment, the components listed below were combined into a tablet, using simple mixing procedures.

Table 1

	<u>Component</u>	<u>Amount</u>
	CLA	500 mg
	DHA	125 mg
20	Vitamin E	50 IU
	Vitamin C	60 mg
	Folic Acid	400 µg
	Vitamin B6	20 mg
	Vitamin B12	6 µg
25	Calcium	100 mg

The above ingredients all or in part can be:

1. Mixed dried (direct compression process-DCP) with well recognized tableting aid(s)/filler(s), binding agent(s), disintegrant (s) and lubricant(s), as necessary or desired to form a blend that can be directly compressed into tablets; or
2. Wet granulated (Wet Granulation Process-WGP) with well recognized tableting aid(s)/filler(s), granulating agent(s), disintegrant(s) and lubricant(s) as necessary or desired to form a blend that it can be directly compressed into tablets.

Numerous modifications of this invention are encompassed by the above description and the scope of the following claims. For example, other suitable optional ingredients may be employed in the composition of this invention which are 10 obvious to one of skill in the art considering the present disclosure. Similarly other systemic disorders other than those described may be treated with the compositions of this invention. It should be understood therefore that various changes may be made in the products and processes herein described without significantly affecting the resultant formulations or their use in medical treatment. Various modifications 15 in conditions of preparation such as time and temperature, or changes in administrative procedure or dosages differing from those given herein as illustrative of the preferred embodiments of the invention, may be made without departure from the scope of the invention envisioned by the inventor.

All publications, including but not limited to patents and patent applications, 20 cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

WHAT IS CLAIMED IS:

1. A composition for oral administration comprising conjugated linoleic acid (CLA), an omega-3 fatty acid, vitamin E, vitamin C, vitamin B6, vitamin B12, 5 folic acid and calcium.
 2. The composition according to claim 1 wherein the composition is a stable emulsion.
- 10 3. The composition according to claim 1, wherein said mixture contains about 300 mg to about 2000 mg CLA.
4. The composition according to claim 3, wherein said mixture contains about 500 mg CLA.
- 15 5. The composition according to claim 1, wherein the omega-3 fatty acid is docosahexaenoic acid (DHA) which is present in an amount of about 125 mg to about 500 mg DHA.
- 20 6. The composition according to claim 5, wherein said mixture contains about 125 mg DHA.
7. The composition according to claim 1, wherein said mixture contains about 50 IU to about 500 IU vitamin E.

8. The composition according to claim 7, wherein said mixture contains about 100 IU vitamin E.

5 9. The composition according to claim 1, wherein said mixture contains about 60 mg to about 1000 mg vitamin C.

10. The composition according to claim 9, wherein said mixture contains about 60 mg vitamin C.

10

11. The composition according to claim 1, wherein said mixture contains about 400 µg to about 1000 µg folic acid.

12. The composition according to claim 11, wherein said mixture
15 contains about 400 µg folic acid.

13. The composition according to claim 1, wherein said mixture contains about 2 mg to about 50 mg vitamin B6.

20 14. The composition according to claim 13, wherein said mixture contains about 20 mg vitamin B6.

15. The composition according to claim 1, wherein said mixture contains about 6 µg to about 1 mg vitamin B12.

25

16. The composition according to claim 1, wherein said mixture contains

about 6 µg vitamin B12.

17. The composition according to claim 1, wherein said mixture contains about 200 mg to 1000 mg calcium.

5

18. The composition according to claim 1 wherein the mixture is in a solid dosage form which is a tablet, capsule, soft gelatin capsule, or sachet.

19. A method for reducing risk factors associated with cardiovascular disease in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

20. A method for preventing oxidation of low density lipoprotein in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

21. A method for increasing high density lipoprotein in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

20

22. A method for reducing total cholesterol in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

25 23. A method for reducing triglycerides in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

24. A method for reducing homocysteine in a mammal in need thereof, which method comprised orally administering to said mammal a composition according to any one of claims 1 to 17.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/043662 A3

(51) International Patent Classification⁷: A61K 9/14,
9/20, 9/48

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/44872

(22) International Filing Date:
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/253,897 29 November 2000 (29.11.2000) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BENDICH, Adrienne**
[US/US]; 1500 Littleton Road, Parsippany, NJ 07054 (US).

(74) Agents: **DINNER, Dara, L.** et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
23 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/043662 A3

(54) Title: DIETARY COMPOSITION CONTAINING CONJUGATED LINOLEIC ACID AND CALCIUM FOR IMPROVED HEALTH

(57) Abstract: The invention provides a composition for oral administration comprising a mixture of conjugated linoleic acid (CLA), docosahexaenoic acid "DHA", vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors of cardiovascular disease, such as elevated serum cholesterol levels and high blood pressure.

INTERNATIONAL SEARCH REPORT

I	nternational Application No
	PCT/US 01/46997

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01S13/89

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01S

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, INSPEC, COMPENDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SOUmekh M: "Wide-bandwidth continuous-wave monostatic/bistatic synthetic aperture radar imaging" IMAGE PROCESSING, 1998. ICIP 98. PROCEEDINGS. 1998 INTERNATIONAL CONFERENCE ON CHICAGO, IL, USA 4-7 OCT. 1998, LOS ALAMITOS, CA, USA, IEEE COMPUT. SOC, US, 4 October 1998 (1998-10-04), pages 361-365, XP010309086 ISBN: 0-8186-8821-1 Section III. Bistatic WB-CW SAR, page 363-364</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,7,9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 August 2002

Date of mailing of the international search report

06/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Niemeijer, R

INTERNATIONAL SEARCH REPORT

In	International Application No
PCT/US 01/46997	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CICHON D J ET AL: "Bistatic Scattering For Synthetic Apertures In Remote Sensing" INTERNATIONAL SPACE YEAR: SPACE REMOTE SENSING. HOUSTON, MAY 26 - 29, 1992, PROCEEDINGS OF THE INTERNATIONAL GEOSCIENCE AND REMOTE SENSING SYMPOSIUM (IGARSS), NEW YORK, IEE, US, vol. 1 SYMP. 12, 26 May 1992 (1992-05-26), pages 643-645, XP010101231 ISBN: 0-7803-0138-2 page 643; figure 1</p> <p>---</p>	1,7,9
A	<p>OGRODNIK R F: "Bistatic laptop radar: an affordable, silent radar alternative" RADAR CONFERENCE, 1996., PROCEEDINGS OF THE 1996 IEEE NATIONAL ANN ARBOR, MI, USA 13-16 MAY 1996, NEW YORK, NY, USA, IEEE, US, 13 May 1996 (1996-05-13), pages 369-373, XP010164781 ISBN: 0-7803-3145-1 Section Introduction, page 369-371; figure 1</p> <p>---</p>	1,7,9
A	<p>OGRODNIK R F: "Fusion techbroad area surveillance exploiting ambient signals via coherent techniques" MULTISENSOR FUSION AND INTEGRATION FOR INTELLIGENT SYSTEMS, 1994. IEEE INTERNATIONAL CONFERENCE ON MFI '94. LAS VEGAS, NV, USA 2-5 OCT. 1994, NEW YORK, NY, USA, IEEE, 2 October 1994 (1994-10-02), pages 421-429, XP010137967 ISBN: 0-7803-2072-7 page 421</p> <p>-----</p>	1,7,9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/44872

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/14, 9/20, 9/48
US CL : 424/451, 452, 464, 465, 489

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 424/451, 452, 464, 465, 489

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
West

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,126,960 A (NILSEN et al.) 03 October 2000 (03.10.2000); see columns 3-4, columns 7-8, column 9, lines 15-61, column 10-12, and examples 1-9.	1-18
P	US 6,420,342 A (HAGEMAN et al.) 16 July 2002 (16.07.2002); see columns 5-12, and examples.	1-18

Further documents are listed in the continuation of Box C.

See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

01 August 2002 (01.08.2002)

Date of mailing of the international search report

26 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703)305-3230

Authorized officer

Susan P. Tran

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/44872

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-18

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US01/44872

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: they do not share the same essential elements that define the "special technical feature" necessary to specify a contribution over the prior art. The element common to all the groups is a composition comprising acids and vitamins, which is known in the art and, therefore, cannot be said to be the special technical feature which makes a contribution over the prior art. All other elements differ from each other, e.g., the method for reducing total cholesterol, method for reducing triglycerides, method for preventing oxidation of low density lipoprotein, method for reducing risk factors associated with cardiovascular, each of which are known in the prior art. Thus, these claims lack the corresponding special technical features necessary to link them together to fulfill the Unity of Invention requirement.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-18, drawn to composition for oral administration.

Group II, claim 19, drawn to method for reducing risk factors associated with cardiovascular.

Group III, claims 20 and 21, drawn to method for preventing and increasing oxidation of low density lipoprotein.

Group IV, claim 22, drawn to method for reducing total cholesterol in a mammal.

Group V, claim 23, drawn to method for reducing triglycerides in a mammal.

Group VI, claim 24, drawn to method for reducing homocysteine in a mammal.